{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T14:43:38Z","timestamp":1740149018073,"version":"3.37.3"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T00:00:00Z","timestamp":1686873600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T00:00:00Z","timestamp":1686873600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"New Seed Fund of West China Second University Hospital, Sichuan University","award":["kz022"],"award-info":[{"award-number":["kz022"]}]},{"name":"the Horizontal Topic of Sichuan University","award":["22H0226"],"award-info":[{"award-number":["22H0226"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Genomics"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Most endometrial cancers are of low histological grade and uterine-confined, with a high 5-year survival rate. However, a small subset of women with low-grade and early-stage endometrioid endometrial cancer experience recurrence and death; thus, a more precise risk-stratification is needed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>A 29-year-old woman presented with abnormal vaginal bleeding and was diagnosed with FIGO grade 1 endometrioid endometrial carcinoma by curettage. Comprehensive cancer staging including pelvic and para-aortic lymphadenectomy was then performed. Postoperative pathological findings suggested an FIGO grade 1 endometrioid endometrial carcinoma infiltrating the superficial muscle layer. The patient did not receive adjuvant therapy. After 4\u00a0years of follow-up, the patient returned to our institution with lung metastasis. She underwent thoracoscopic resection of the affected lobes, followed by six cycles of combined chemotherapy of paclitaxel and carboplatin. Next-generation sequencing showed that the primary and lung metastatic tumors shared 4 mutations: <jats:italic>PTEN<\/jats:italic> (p.P248Lfs*8), <jats:italic>CTNNB1<\/jats:italic> (p.D32A), <jats:italic>BCOR<\/jats:italic> (p.N1425S) and <jats:italic>CBL<\/jats:italic> (p.S439N). Immunohistochemistry revealed nuclear location of \u03b2\u2013catenin in the primary and lung metastatic tumor samples, indicating abnormal activation of \u03b2\u2013catenin.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p><jats:italic>CTNNB1<\/jats:italic>p.D32A (c.95A\u2009&gt;\u2009C) mutation may be related to lung metastasis in this patient with low-grade early-stage endometrioid endometrial carcinoma.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12920-023-01570-3","type":"journal-article","created":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T10:01:57Z","timestamp":1686909717000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["CTNNB1 p.D32A (c.95A\u2009&gt;\u2009C) somatic mutation in stage I grade 1 endometrioid endometrial carcinoma with lung metastasis: a case report"],"prefix":"10.1186","volume":"16","author":[{"given":"Lan","family":"Zhong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"RutieYin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4206-2990","authenticated-orcid":false,"given":"Liang","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,6,16]]},"reference":[{"issue":"1","key":"1570_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21551","volume":"69","author":"Rl Siegel","year":"2019","unstructured":"Siegel Rl, Miller Kd, Jemal A. Cancer Statistics, 2019. Ca Cancer J Clin. 2019;69(1):7\u201334.","journal-title":"Ca Cancer J Clin"},{"issue":"2","key":"1570_CR2","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.ygyno.2008.10.019","volume":"112","author":"T Fujimoto","year":"2009","unstructured":"Fujimoto T, Nanjyo H, Fukuda J, et al. Endometrioid uterine cancer: histopathological risk factors of local and distant recurrence. Gynecol Oncol. 2009;112(2):342\u20137.","journal-title":"Gynecol Oncol"},{"issue":"6","key":"1570_CR3","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1136\/ijgc-2020-001241","volume":"30","author":"M Stasenko","year":"2020","unstructured":"Stasenko M, Feit N, Ssk L, et al. Clinical patterns and genomic profiling of recurrent \u2018Ultra-Low Risk\u2019 endometrial cancer. Int J Gynecol Cancer. 2020;30(6):717\u201323.","journal-title":"Int J Gynecol Cancer"},{"issue":"16","key":"1570_CR4","doi-asserted-by":"publisher","first-page":"4215","DOI":"10.1158\/1078-0432.CCR-15-2878","volume":"22","author":"E Stelloo","year":"2016","unstructured":"Stelloo E, Nout RA, Osse EM. Improved Risk Assessment By Integrating Molecular And Clinicopathological Factors In Early-Stage Endometrial Cancer-Combined Analysis Of The Portec Cohorts. Clin Cancer Res. 2016;22(16):4215\u201324.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"1570_CR5","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.ygyno.2019.03.247","volume":"153","author":"V Jt","year":"2019","unstructured":"Jt V, Ek L, Ea G, et al. Diagnosis and management of a recurrent polymerase-epsilon (Pole)-mutated endometrial cancer. Gynecol Oncol. 2019;153(3):471\u20138.","journal-title":"Gynecol Oncol"},{"key":"1570_CR6","doi-asserted-by":"publisher","unstructured":"Liu Y, Patel L, Mills GB, Lu KH, Sood AK, Ding L, Kucherlapati R, Mardis ER, Levine DA, Shmulevich I, Broaddus RR, Zhang W. Clinical significance of CTNNB1 mutation and Wnt pathway activation in endometrioid endometrial carcinoma. J Natl Cancer Inst. 2014;106(9):dju245. https:\/\/doi.org\/10.1093\/jnci\/dju245.","DOI":"10.1093\/jnci\/dju245"},{"issue":"7","key":"1570_CR7","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1038\/modpathol.2017.15","volume":"30","author":"K Kc","year":"2017","unstructured":"Kc K, Gn K, Bm F, et al. Ctnnb1 (Beta-Catenin) mutation identifies low grade, early stage endometrial cancer patients at increased risk of recurrence. Mod Pathol. 2017;30(7):1032\u201341.","journal-title":"Mod Pathol"},{"issue":"3","key":"1570_CR8","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.ygyno.2019.03.100","volume":"153","author":"M Mr","year":"2019","unstructured":"Mr M, Davies Kd, Ac W, et al. Molecular markers in recurrent stage I, Grade 1 endometrioid endometrial cancers. Gynecol Oncol. 2019;153(3):517\u201320.","journal-title":"Gynecol Oncol"},{"issue":"2","key":"1570_CR9","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1097\/PGP.0000000000000583","volume":"39","author":"DC Costigan","year":"2020","unstructured":"Costigan DC, Dong F, Nucci MR, Howitt BE. Clinicopathologic And Immunohistochemical Correlates Of Ctnnb1 Mutated Endometrial Endometrioid Carcinoma. Int J Gynecol Pathol. 2020;39(2):119\u201327.","journal-title":"Int J Gynecol Pathol"},{"key":"1570_CR10","doi-asserted-by":"publisher","unstructured":"Nero C, Ciccarone F, Pietragalla A, Scambia G. PTEN and Gynecological Cancers. Cancers (Basel). 2019;11(10):1458. https:\/\/doi.org\/10.3390\/cancers11101458.","DOI":"10.3390\/cancers11101458"},{"issue":"6","key":"1570_CR11","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1007\/s00404-019-05123-x","volume":"299","author":"A Raffone","year":"2019","unstructured":"Raffone A, Travaglino A, Saccone G, et al. Pten expression in endometrial hyperplasia and risk of cancer: a systematic review and meta-analysis. Arch Gynecol Obstet. 2019;299(6):1511\u201324.","journal-title":"Arch Gynecol Obstet"},{"issue":"2","key":"1570_CR12","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1158\/2159-8290.CD-11-0039","volume":"1","author":"LW Cheung","year":"2011","unstructured":"Cheung LW, Hennessy BT, Li J, et al. High Frequency Of Pik3r1 And Pik3r2 Mutations In Endometrial Cancer Elucidates A Novel Mechanism For Regulation Of Pten Protein Stability. Cancer Discov. 2011;1(2):170\u201385.","journal-title":"Cancer Discov"},{"issue":"2","key":"1570_CR13","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.ygyno.2014.06.010","volume":"134","author":"A Myers","year":"2014","unstructured":"Myers A, Barry WT, Hirsch MS, Matulonis U, Lee L. \u0392-Catenin Mutations In Recurrent Figo Ia Grade I Endometrioid Endometrial Cancers. Gynecol Oncol. 2014;134(2):426\u20137.","journal-title":"Gynecol Oncol"},{"issue":"4","key":"1570_CR14","doi-asserted-by":"publisher","first-page":"5492","DOI":"10.18632\/oncotarget.23695","volume":"9","author":"C Gao","year":"2018","unstructured":"Gao C, Wang Y, Broaddus R, Sun L, Xue F, Zhang W. Exon 3 mutations of ctnnb1 drive tumorigenesis: a review. Oncotarget. 2018;9(4):5492\u2013508.","journal-title":"Oncotarget"},{"issue":"2","key":"1570_CR15","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/S0002-9440(10)64856-0","volume":"160","author":"NA Wong","year":"2002","unstructured":"Wong NA, Pignatelli M. Beta-Catenin--A Linchpin In Colorectal Carcinogenesis. Am J Pathol. 2002;160(2):389\u2013401.","journal-title":"Am J Pathol"},{"issue":"2","key":"1570_CR16","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1053\/hupa.2002.30723","volume":"33","author":"P Machin","year":"2002","unstructured":"Machin P, Catasus L, Pons C, Mu\u00f1oz J, Matias-Guiu X, Prat J. Ctnnb1 mutations and beta-catenin expression in endometrial carcinomas. Hum Pathol. 2002;33(2):206\u201312.","journal-title":"Hum Pathol"},{"key":"1570_CR17","doi-asserted-by":"crossref","unstructured":"Provost E, Mccabe A, Stern J, Lizardi I, D\u2019aquila TG, Rimm Dl. Functional Correlates Of Mutation Of The Asp32 And Gly34 Residues Of Beta-Catenin. Oncogene. 2005;24(16):2667\u201376.","DOI":"10.1038\/sj.onc.1208346"},{"issue":"34","key":"1570_CR18","doi-asserted-by":"publisher","first-page":"31781","DOI":"10.1074\/jbc.M304953200","volume":"278","author":"E Provost","year":"2003","unstructured":"Provost E, Yamamoto Y, Lizardi I, et al. Functional correlates of mutations in beta-catenin exon 3 phosphorylation sites. J Biol Chem. 2003;278(34):31781\u20139.","journal-title":"J Biol Chem"}],"container-title":["BMC Medical Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12920-023-01570-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12920-023-01570-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12920-023-01570-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T10:04:17Z","timestamp":1686909857000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedgenomics.biomedcentral.com\/articles\/10.1186\/s12920-023-01570-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,16]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1570"],"URL":"https:\/\/doi.org\/10.1186\/s12920-023-01570-3","relation":{},"ISSN":["1755-8794"],"issn-type":[{"type":"electronic","value":"1755-8794"}],"subject":[],"published":{"date-parts":[[2023,6,16]]},"assertion":[{"value":"14 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Ethics Committee of West China Second University Hospital of Sichuan University (2020076), and the patient provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from this patient for the publication of any identifying information and\/or clinical details included in this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"137"}}